3//SEC Filing
Israel Biotech Fund I, L.P. 3
Accession 0001178913-23-003117
CIK 0001100397other
Filed
Sep 10, 8:00 PM ET
Accepted
Sep 11, 12:41 PM ET
Size
5.4 KB
Accession
0001178913-23-003117
Insider Transaction Report
Form 3
Israel Biotech Fund I, L.P.
10% Owner
Holdings
- 621,253(indirect: See footnote)
Common Stock, par value $0.001 per share
Footnotes (2)
- [F1]The reported shares are held of record by Israel Biotech Fund I, L.P. ("IBF 1"). These shares were received by IBF 1 as a result of the merger, on or about January 19, 2023, of Old Ayala, Inc. (f/k/a Ayala Pharmaceuticals, Inc.) ("Old Ayala") with a wholly-owned subsidiary of the Issuer (f/k/a Advaxis, Inc.), pursuant to an Agreement and Plan of Merger (the "Advaxis Merger Agreement"), dated October 18, 2022, by and among the Issuer, Old Ayala and Doe Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Issuer.
- [F2]Israel Biotech Fund GP Partners, L.P. ("IBF I GP"), a Cayman Islands Exempted Limited Partnership, is the general partner of IBF 1. I.B.F Management Ltd. ("IBF Management"), an Israeli private company, is the management company of IBF I GP. By virtue of such relationships, IBF 1 GP and IBF Management may be deemed to have shared voting and investment power with respect to the shares held of record by IBF 1. Each of IBF 1 GP and IBF Management disclaims beneficial ownership of the shares held by IBF 1, except to the extent of their pecuniary interest therein, if any.
Documents
Issuer
Ayala Pharmaceuticals, Inc.
CIK 0001100397
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001652458
Filing Metadata
- Form type
- 3
- Filed
- Sep 10, 8:00 PM ET
- Accepted
- Sep 11, 12:41 PM ET
- Size
- 5.4 KB